Clinical investigation of the effects of pioglitazone in the diabetic patients with hemodilaysis

Clinical investigation of the effects of pioglitazone in the diabetic patients with hemodilaysis - The effects of pioglitazone

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002643

Enrollment

Registered

2009-10-19

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patients with hemodialysis

Interventions

Oral antidiabetic agents other than pioglitazone pioglitazone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Type 2 diabetic patients with hemodialysis. 2)Poorly glycemic control defined as a hemoglobin A1c (HbA1c) level >6.5% after 12 consecutive weeks of daily administration of conventional anti-diabetic agents.

Exclusion criteria

Exclusion criteria: The exclusion criteria are the patients treated with insulin, cirrhosis or deranged liver function at baseline; prior history of heart failure (both systolic and diastolic), myocardial infarction, or symptomatic coronary artery disease; significant aortic or mitral valve heart disease; New York Heart Association (NYHA) class 3 or 4 cardiac status; thyroid disease, or malignant tumour; history of gastrointestinal or other major bleeding within the last 6 months; and treatment with steroids.

Design outcomes

Primary

Measure	Time frame
Glycemic control Adverse effects	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026